AstraZeneca, a leading global biopharmaceutical company, has partnered with Revna Biosciences, a Ghanaian precision medicine and diagnostics company, to introduce EGFR biomarker testing for non-small cell lung cancer (NSCLC) patients in Ghana. The collaboration marks a significant step toward early cancer detection and targeted therapy tailored to each patient’s unique genetic profile.
The EGFR (Epidermal Growth Factor Receptor) gene, a known driver of lung cancer, is key to determining the most effective, personalized treatments. Through enhanced EGFR testing capabilities, the initiative aims to improve diagnostic accuracy and clinical outcomes, moving away from traditional chemotherapy toward more precise, less invasive cancer care.
Dr. Khomotso Mashilane, Medical Director for AstraZeneca’s African Cluster, emphasized that this partnership reflects a deep commitment to strengthening healthcare systems and expanding access to innovative cancer treatments across Africa. “Today’s patients are at the heart of our work,” she said, “and with tomorrow’s targeted therapies, hope will become a reality.”
The partnership also includes:
- Mapping the patient journey from diagnosis to treatment.
- Training healthcare professionals through workshops and education programs.
- Improving early detection and clinical outcomes through precision medicine.
Dr. Derrick Edem Akpalu, CEO of Revna Biosciences, called the collaboration a timely response to Ghana’s growing demand for personalized healthcare. “Together, we aim to raise awareness, increase access to life-saving treatments, and ensure every patient has the best chance to thrive,” he said.
The rollout will begin soon, starting with onboarding of medical professionals and launch of the first training workshops—bringing Ghana one step closer to world-class cancer care.
